To evaluate the potential predictive value of CTLA4 methylation prior to immunotherapy, we have assembled a multicenter ICB treated cohort (RCC-ICB Cohort, n=71) of patients treated at German tertiary referral centers. The gene discussed is CTLA4; the disease is renal cell carcinoma.